510 k Premarket Notification Pulpdent Semi-Gel Etch

EXHIBIT 2

SUMMARY OF SAFETY AND EFFECTIVENESS DATA

K022492

Kenneth J. Berk 80 Oakland Street P D Box '80 V atertovn, MA 02472 USA Telephone:

617-926-6666

Fax:

617-926-6262

Email: Pulpdent@pulpdent.com

I EVICE NAME:

PULPDENT Semi-Gel Etch

PREDICATE DEVICES:

Pulpdent Etch-Rite 38 % Phosphoric Acid Etching Gel

Pulpdent Etch-All 10 % Phosphoric Acid Etching Gel

Ortho Direct Enamel Etch

DESCRIPTION AND INTENDED USE:

Pulpdent Semi-Gel Etch is a 35% phosphoric acid etchant in a viscous liquid form. It is used by the dental professional to etch dentin, enamel and glass ionomer cements.

COMFARISON WITH PREDICATE PRODUCTS:

PULP DENT Semi-Gel Etch is substantially equivalent in design, composition and intended use to the products listed above. Please see Exhibit 4 for the entire comparison.

SAFETY AND EFFECTIVENESS:

Gene al usage of the predicate products over more than 10 years indicates a high benefit-to-risk ratio. There is no evidence of short-term or long-term risk or suspicion of any problems. In addition, the predicate products listed above have been given 510 (k) Premarket approval as Class II Dental Devices under CFR 872.3690. Please see Exhibit 4 for 510(k) numbers.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

OCT 1 1 2002

Mr. Kenneth J. Berk
Director
Pulpdent Corporation
80 Oakland Street
Watertown, Massachusetts 02472

Re: K022492

Trade/Device Name: Pulpdent Semi-Gel Etch

Regulation Number: 872.3670

Regulation Name: Resin Impression Tray Material

Regulatory Class: II Product Code: 76 EBF Dated: July 25, 2002 Received: July 29, 2002

Dear Mr. Berk:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.

You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Timothy A. Ulatowski

Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices

filmen Circente fle

Office of Device Evaluation

Center for Devices and

Radiological Health

INDICATIONS FOR USE STATEMENT

510 (k) Number

(if known)					
Device Name	PULPDENT	SEMI-GEL ETC	Н		
Indications for U PUL PDEIIT SEM form. It is used to	<i>II-GEL ETCH</i> is	s a 35% phosp rofessional to et	horic acid etch ch dentin, enar	ant in a v nel and gl	iscous liquid ass ionomer
F'lease do	not write below	this line. Conti	inue on another	page if ne	eded.
		DRH, Office of D		<u></u>	
Frescription Use		or	Ove	er-The-Cou	ınter Use
	Division o	Sign-Off) Sign-Off) of Anesthesiology, G Control, Dental Devi	eneral Hospital.	ler	